Advertisement

Current Drug Therapy for Underactive Bladder

  • Michael B. ChancellorEmail author

Abstract

Muscarinic agonists are the most commonly used drugs for treating the underactive bladder (UAB). Many clinicians who treat UAB patients will use bethanechol but most physicians will also acknowledge that bethanechol is not helpful for the majority of their UAB patients. Clinical utility of current parasympathomimetic treatment of UAB is limited by low pharmacologic specificity for the urinary bladder and common side effects. This chapter will review the use of parasympathetic agents to treat UAB. This will be followed by chapters that will focus on advances in treatment of UAB including Chaps. 7, 8, 9, and 10.

Keywords

Muscarinic Receptor Radical Hysterectomy Detrusor Contraction Residual Urine Volume Detrusor Underactivity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178CrossRefPubMedGoogle Scholar
  2. Barendrecht MM, Oelke M, Laguna MP, Michel MC (2007) Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 99:749–752CrossRefPubMedGoogle Scholar
  3. Barrett DM (1981) The effect of oral bethanechol chloride on voiding in female patients with excessive residual urine: a randomized double-blind study. J Urol 126:640–642PubMedGoogle Scholar
  4. Braverman AS, Kohn IJ et al (1998) Prejunctional M1 facilitatory and M2 inhibitory muscarinic receptors mediate rat bladder contractility. Am J Physiol 274(2 Pt 2):R517–R523PubMedCentralPubMedGoogle Scholar
  5. Burger DH, Kappetein AP, Boutkan H, Breslau PJ (1997) Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfuzosine. J Am Coll Surg 185:234–236CrossRefPubMedGoogle Scholar
  6. Chancellor MB, Diokno A (2014) CURE-UAB: shedding light on the underactive bladder syndrome. Int Urol Nephrol 46(Suppl 1):S1–S46CrossRefPubMedGoogle Scholar
  7. Fleming AR (1957) The use of urecholine in the prevention of postpartum urinary retention; final report. Am J Obstet Gynecol 74:569–571CrossRefPubMedGoogle Scholar
  8. Gottesman L, Milsom JW, Mazier WP (1989) The use of anxiolytic and parasympathomimetic agents in the treatment of postoperative urinary retention following anorectal surgery. A prospective, randomized, double-blind study. Dis Colon Rectum 32:867–870CrossRefPubMedGoogle Scholar
  9. Hegde SS (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147(Suppl 2):S80–S87PubMedCentralCrossRefPubMedGoogle Scholar
  10. Hindley RG, Brierly RD, Thomas PJ (2004) Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity. BJU Int 93:89–92CrossRefPubMedGoogle Scholar
  11. Kemp B, Kitschke HJ, Goetz M, Heyl W (1997) Prophylaxis and treatment of bladder dysfunction after Wertheim–Meigs operation: the positive effect of early postoperative detrusor stimulation using the cholinergic drug betanecholchloride. Int Urogynecol J Pelvic Floor Dysfunct 8:138–141CrossRefPubMedGoogle Scholar
  12. Krishnamoorthy S, Kekre NS (2009) Detrusor underactivity: to tone or not to tone the bladder? Indian J Urol 25:407–408PubMedCentralCrossRefPubMedGoogle Scholar
  13. Madeiro AP, Rufino AC, Sartori MG, Baracat EC, Lima GR, Girão MJ (2006) The effects of bethanechol and cisapride on urodynamic parameters in patients undergoing radical hysterectomy for cervical cancer. A randomized, double-blind, placebo-controlled study. Int Urogynecol J Pelvic Floor Dysfunct 17:248–252CrossRefPubMedGoogle Scholar
  14. Manchana T, Prasartsakulchi C (2011) Bethanechol chloride for the prevention of bladder dysfunction after radical hysterectomy in gynecologic cancer patients: a randomized controlled trial study. Int J Gynecol Cancer 21:730–736PubMedGoogle Scholar
  15. Osman NI, Chapple CR, Abrams P, Dmochowski R, Haab F, Nitti V, Koelbl H, van Kerrebroeck P, Wein AJ (2014) Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol 65:389–398CrossRefPubMedGoogle Scholar
  16. Oxford Centre for Evidence-Based Medicine: Levels of evidence and grades of recommendation (2001) Available at: http://www.cebm.net/levels_of_evidence.asp. Accessed Nov 2006
  17. Riedl CR, Daha LK, Knoll M, Pflueger H (2002) Bethanechol in the restitution of the acontractile detrusor: a prospective, randomized, double blind, placebo-controlled study. Neurourol Urodyn 21:376Google Scholar
  18. Savona-Ventura C, Grech ES, Saliba I (1991) Pharmacological measures to prevent post-operative urinary retention; a prospective randomized study. Eur J Obstet Gynecol Reprod Biol 41:225–229CrossRefPubMedGoogle Scholar
  19. Shah PJ, Abrams PH, Choa RG et al (1983) Distigmine bromide and post-prostatectomy voiding. Br J Urol 55:229–232CrossRefPubMedGoogle Scholar
  20. Smith PP (2010) Aging and the underactive detrusor: a failure of activity or activation? Neurourol Urodyn 29:408–412PubMedGoogle Scholar
  21. Smith PP, Tyagi P, Kuchel GA et al (2014) Advanced therapeutic directions to treat the underactive bladder. Int Urol Nephrol 46(Suppl 1):S35CrossRefPubMedGoogle Scholar
  22. Somogyi GT, de Groat WC (1992) Evidence for inhibitory nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder. J Auton Nerv Syst 37:S89–S97CrossRefGoogle Scholar
  23. Somogyi GT, Tanowitz M et al (1996) M1 muscarinic receptor facilitation of ACh and noradrenaline release in the rat urinary bladder is mediated by protein kinase C. J Physiol 496:245–254PubMedCentralCrossRefPubMedGoogle Scholar
  24. Tomoe H (2014) Assessment of the usefulness and optimal method of administration of distigmine bromide for the treatment of voiding dysfunction due to underactive detrusor. Paper presented at the AUGS/IUGA Scientific Meeting. Washington, DC. 22–26 July 2014Google Scholar
  25. Tyagi P, Smith PP, Kuchel GA et al (2014) Pathophysiology and animal modeling of underactive bladder. Int Urol Nephrol 46(Suppl 1):S11PubMedCentralCrossRefPubMedGoogle Scholar
  26. Yamaguchi O, Shishido K et al (1996) Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J Urol 156:1208–1213CrossRefPubMedGoogle Scholar
  27. Yamanishi T, Yasuda K, Kamai T et al (2004) Combination of a cholinergic drug and an α-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol 11:88–96CrossRefPubMedGoogle Scholar
  28. Yoshimura N, Chancellor MB (2011) Physiology and pharmacology of the bladder and urethra. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbells urology. 10th edn Elsevier, Philadelphia, PA, USAGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Urology, Aikens Research CenterOakland University William Beaumont School of MedicineRochesterUSA
  2. 2.Neurourology ProgramBeaumont Health SystemRoyal OakUSA

Personalised recommendations